View ValuationGreen Lifescience 将来の成長Future 基準チェック /06現在、 Green Lifescienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長23.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩2,430, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total loss to shareholders of 20% over the past three years.分析記事 • May 27Green Lifescience's (KOSDAQ:114450) Earnings Are Weaker Than They SeemInvestors were disappointed with Green Lifescience Co., Ltd.'s ( KOSDAQ:114450 ) earnings, despite the strong profit...New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩58.9b market cap, or US$39.0m).New Risk • May 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₩71.2b market cap, or US$47.8m).お知らせ • Feb 26Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South Korea分析記事 • Dec 25Lacklustre Performance Is Driving Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 26% Price DropGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shares have retraced a considerable 26% in the last month, reversing a...分析記事 • Oct 31There Is A Reason Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Price Is UndemandingGreen Lifescience Co., Ltd.'s ( KOSDAQ:114450 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy...分析記事 • Aug 18Is Green Lifescience (KOSDAQ:114450) Weighed On By Its Debt Load?KOSDAQ:A114450 1 Year Share Price vs Fair Value Explore Green Lifescience's Fair Values from the Community and select...分析記事 • Jul 11Revenues Working Against Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Share Price Following 34% DiveThe Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) share price has softened a substantial 34% over the previous 30 days...分析記事 • Jun 25Estimating The Intrinsic Value Of Green Lifescience Co., Ltd. (KOSDAQ:114450)Key Insights Using the 2 Stage Free Cash Flow to Equity, Green Lifescience fair value estimate is ₩3,081 With ₩3,185...Buy Or Sell Opportunity • Jun 11Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 145% to ₩4,065. The fair value is estimated to be ₩3,077, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has declined by 42%.New Risk • May 28New major risk - Revenue and earnings growthEarnings have declined by 41% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩77.0b market cap, or US$56.0m).分析記事 • May 21Improved Revenues Required Before Green Lifescience Co., Ltd. (KOSDAQ:114450) Stock's 38% Jump Looks JustifiedGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shareholders would be excited to see that the share price has had a great...New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩43.1b market cap, or US$31.3m).Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩2,205, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total loss to shareholders of 46% over the past three years.分析記事 • Mar 06Is Green Lifescience (KOSDAQ:114450) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Feb 27Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩34.8b market cap, or US$24.2m).分析記事 • Dec 09Why Investors Shouldn't Be Surprised By Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 27% Share Price PlungeGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shareholders that were waiting for something to happen have been dealt a...分析記事 • Nov 13Is Green Lifescience (KOSDAQ:114450) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Sep 13Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 36% Dip In Price Shows Sentiment Is Matching RevenuesThe Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) share price has softened a substantial 36% over the previous 30 days...New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₩34.3b market cap, or US$25.1m).分析記事 • Jul 30The Market Doesn't Like What It Sees From Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Revenues YetYou may think that with a price-to-sales (or "P/S") ratio of 1.7x Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) is...分析記事 • Mar 26Health Check: How Prudently Does Green Lifescience (KOSDAQ:114450) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩48.9b market cap, or US$37.5m).お知らせ • Aug 23Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces an Equity Buyback for KRW 2,000 million worth of its shares.Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares, pursuant the contract with Yuanta Securities Korea Co., Ltd. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on March 6, 2024. As of August 21, 2023, the company had no shares in treasury within scope available for dividend and no shares in treasury through other repurchase.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Feb 22KPX Lifescience.Co.Ltd (KOSDAQ:114450) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Feb 22KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021, at 09:00 Korea Standard Time.Is New 90 Day High Low • Feb 17New 90-day low: ₩9,330The company is down 60% from its price of ₩23,250 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.Is New 90 Day High Low • Jan 31New 90-day low: ₩9,580The company is down 1.0% from its price of ₩9,700 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 16% over the same period.分析記事 • Dec 31Investors Who Bought KPX Lifescience.Co.Ltd (KOSDAQ:114450) Shares Three Years Ago Are Now Up 180%KPX Lifescience.Co.,Ltd. ( KOSDAQ:114450 ) shareholders might be concerned after seeing the share price drop 26% in the...Is New 90 Day High Low • Nov 06New 90-day high: ₩12,550The company is up 77% from its price of ₩7,110 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period.Is New 90 Day High Low • Oct 20New 90-day high: ₩9,100The company is up 46% from its price of ₩6,230 on 22 July 2020. The South Korean market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 5.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Green Lifescience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A114450 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202651,0173,011-3,439-1,939N/A12/31/202540,340110-796364N/A9/30/202534,656-366-1,844-1,134N/A6/30/202527,756-1,953-3,479-2,678N/A3/31/202523,191-6424551,366N/A12/31/202424,8611,562-315525N/A9/30/202421,587-12,6642,1633,143N/A6/30/202424,604-12,0404061,121N/A3/31/202424,993-14,416-1,061-563N/A12/31/202322,369-16,358-136370N/A9/30/202323,129-5,177-1,762-1,491N/A6/30/202322,314-5,058-4,434-3,797N/A3/31/202325,900-4,513-1,154-216N/A12/31/202236,505-3,526-6,030-4,552N/A9/30/202239,978-2,267-4,405-1,192N/A6/30/202239,758-2,696-2,3641,055N/A3/31/202234,441-2,524-6,191-2,831N/A12/31/202125,338-3,136-2,832611N/A9/30/202122,361-2,615-3,314-866N/A6/30/202121,203-1,928-4,452-2,198N/A3/31/202124,440-854-1,1871,590N/A12/31/202024,561-1,059-7651,902N/A9/30/202028,036-8-1,2261,897N/A6/30/202031,8754281,1535,036N/A3/31/202033,657140-9432,021N/A12/31/201937,6181,196N/A4,242N/A9/30/201934,305-601N/A3,463N/A6/30/201934,030-815N/A3,597N/A3/31/201931,294-1,551N/A5,377N/A12/31/201832,754-1,445N/A5,377N/A9/30/201836,947-607N/A4,497N/A6/30/201839,978433N/A2,812N/A3/31/201842,115953N/A3,865N/A12/31/201742,5852,225N/A5,681N/A9/30/201741,6654,081N/A5,812N/A6/30/201743,5154,408N/A8,779N/A3/31/201746,1175,239N/A8,558N/A12/31/201643,3044,504N/A7,067N/A9/30/201646,7405,882N/A8,284N/A6/30/201646,1535,667N/A7,760N/A3/31/201646,2195,661N/A8,400N/A12/31/201545,5085,387N/A5,617N/A9/30/201543,5932,262N/A6,111N/A6/30/201542,1411,075N/A3,476N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A114450の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A114450の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A114450の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A114450の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A114450の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A114450の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/12 12:20終値2026/06/12 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Green Lifescience Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩2,430, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 20x in the Life Sciences industry in South Korea. Total loss to shareholders of 20% over the past three years.
分析記事 • May 27Green Lifescience's (KOSDAQ:114450) Earnings Are Weaker Than They SeemInvestors were disappointed with Green Lifescience Co., Ltd.'s ( KOSDAQ:114450 ) earnings, despite the strong profit...
New Risk • May 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩58.9b market cap, or US$39.0m).
New Risk • May 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.3% net profit margin). Market cap is less than US$100m (₩71.2b market cap, or US$47.8m).
お知らせ • Feb 26Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026Green Lifescience Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South Korea
分析記事 • Dec 25Lacklustre Performance Is Driving Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 26% Price DropGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shares have retraced a considerable 26% in the last month, reversing a...
分析記事 • Oct 31There Is A Reason Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Price Is UndemandingGreen Lifescience Co., Ltd.'s ( KOSDAQ:114450 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy...
分析記事 • Aug 18Is Green Lifescience (KOSDAQ:114450) Weighed On By Its Debt Load?KOSDAQ:A114450 1 Year Share Price vs Fair Value Explore Green Lifescience's Fair Values from the Community and select...
分析記事 • Jul 11Revenues Working Against Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Share Price Following 34% DiveThe Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) share price has softened a substantial 34% over the previous 30 days...
分析記事 • Jun 25Estimating The Intrinsic Value Of Green Lifescience Co., Ltd. (KOSDAQ:114450)Key Insights Using the 2 Stage Free Cash Flow to Equity, Green Lifescience fair value estimate is ₩3,081 With ₩3,185...
Buy Or Sell Opportunity • Jun 11Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 145% to ₩4,065. The fair value is estimated to be ₩3,077, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 20% over the last 3 years. Earnings per share has declined by 42%.
New Risk • May 28New major risk - Revenue and earnings growthEarnings have declined by 41% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 41% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩77.0b market cap, or US$56.0m).
分析記事 • May 21Improved Revenues Required Before Green Lifescience Co., Ltd. (KOSDAQ:114450) Stock's 38% Jump Looks JustifiedGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shareholders would be excited to see that the share price has had a great...
New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩43.1b market cap, or US$31.3m).
Valuation Update With 7 Day Price Move • May 21Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩2,205, the stock trades at a trailing P/E ratio of 27.6x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total loss to shareholders of 46% over the past three years.
分析記事 • Mar 06Is Green Lifescience (KOSDAQ:114450) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Feb 27Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025Green Lifescience Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 84, yeosusandan 2-ro, jeollanam-do, yeosu South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩34.8b market cap, or US$24.2m).
分析記事 • Dec 09Why Investors Shouldn't Be Surprised By Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 27% Share Price PlungeGreen Lifescience Co., Ltd. ( KOSDAQ:114450 ) shareholders that were waiting for something to happen have been dealt a...
分析記事 • Nov 13Is Green Lifescience (KOSDAQ:114450) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Sep 13Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 36% Dip In Price Shows Sentiment Is Matching RevenuesThe Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) share price has softened a substantial 36% over the previous 30 days...
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Market cap is less than US$100m (₩34.3b market cap, or US$25.1m).
分析記事 • Jul 30The Market Doesn't Like What It Sees From Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Revenues YetYou may think that with a price-to-sales (or "P/S") ratio of 1.7x Green Lifescience Co., Ltd. ( KOSDAQ:114450 ) is...
分析記事 • Mar 26Health Check: How Prudently Does Green Lifescience (KOSDAQ:114450) Use Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩48.9b market cap, or US$37.5m).
お知らせ • Aug 23Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces an Equity Buyback for KRW 2,000 million worth of its shares.Green Lifescience Co., Ltd. (KOSDAQ:A114450) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its shares, pursuant the contract with Yuanta Securities Korea Co., Ltd. The purpose of the program is stock price stability and shareholder value enhancement. The program will expire on March 6, 2024. As of August 21, 2023, the company had no shares in treasury within scope available for dividend and no shares in treasury through other repurchase.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Feb 22KPX Lifescience.Co.Ltd (KOSDAQ:114450) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Feb 22KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021KPX Lifescience.Co.,Ltd., Annual General Meeting, Mar 18, 2021, at 09:00 Korea Standard Time.
Is New 90 Day High Low • Feb 17New 90-day low: ₩9,330The company is down 60% from its price of ₩23,250 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Jan 31New 90-day low: ₩9,580The company is down 1.0% from its price of ₩9,700 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 16% over the same period.
分析記事 • Dec 31Investors Who Bought KPX Lifescience.Co.Ltd (KOSDAQ:114450) Shares Three Years Ago Are Now Up 180%KPX Lifescience.Co.,Ltd. ( KOSDAQ:114450 ) shareholders might be concerned after seeing the share price drop 26% in the...
Is New 90 Day High Low • Nov 06New 90-day high: ₩12,550The company is up 77% from its price of ₩7,110 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Oct 20New 90-day high: ₩9,100The company is up 46% from its price of ₩6,230 on 22 July 2020. The South Korean market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 5.0% over the same period.